Xiao-bo Huang

[Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase].

Q. Jiang, T. Yuan, Y. Lai, 2020, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.